Sorokin, Alexander V.
Patel, Nidhi
Li, Haiou
Hong, Christin G.
Sampson, Maureen
O’Hagan, Ross
Florida, Elizabeth M.
Teague, Heather L.
Playford, Martin P.
Chen, Marcus Y.
Mehta, Nehal N.
Remaley, Alan T.
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 20 December 2022
Accepted: 21 April 2023
First Online: 27 April 2023
Declarations
:
: Study approval was granted by the National Heart, Lung and Blood Institute institutional review board in keeping with the Declaration of Helsinki. All study participants submitted written informed consent prior to enrollment.
: All authors have seen and agreed to the submitted content of the paper and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria.
: The authors declare that they have no conflicts of interest with the contents of this article. Dr. Alan T. Remaley is a full-time US Government employee. Dr. Nehal N. Mehta has served as a consultant for Amgen, Eli Lilly, and Leo Pharma receiving grants/other payments; as a principal investigator and/or investigator for AbbVie, AstraZeneca, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding and as a principal investigator for the National Institutes of Health receiving grants and/or research funding. All other authors declare no financial disclosures.